Abstract:Receptor targeting with radiolabelled peptides has become very important in nuclear medicine and oncology in the past few years. The overexpression of many peptide receptors in numerous cancers, compared to their relatively low density in physiological organs, represents the molecular basis for in vivo imaging and targeted radionuclide therapy with radiolabelled peptide-based probes. The prototypes are analogs of somatostatin which are routinely used in the clinic. More recent developments include somatostatin analogs with a broader receptor subtype profile or with antagonistic properties. Many other peptide families such as bombesin, cholecystokinin/gastrin, glucagon-like peptide-1 (GLP-1)/exendin, arginine-glycine-aspartic acid (RGD) etc. have been explored during the last few years and quite a number of potential radiolabelled probes have been derived from them. On the other hand, a variety of strategies and optimized protocols for efficient labelling of peptides with clinically relevant radionuclides such as 99mTc, M3+ radiometals (111In, 86/90Y, 177Lu, 67/68Ga), 64/67Cu, 18F or radioisotopes of iodine have been developed. The labelling approaches include direct labelling, the use of bifunctional chelators or prosthetic groups. The choice of the labelling approach is driven by the nature and the chemical properties of the radionuclide. Additionally, chemical strategies, including modification of the amino acid sequence and introduction of linkers/spacers with different characteristics, have been explored for the improvement of the overall performance of the radiopeptides, e.g. metabolic stability and pharmacokinetics. Herein, we discuss the development of peptides as radiopharmaceuticals starting from the choice of the labelling method and the conditions to the design and optimization of the peptide probe, as well as some recent developments, focusing on a selected list of peptide families, including somatostatin, bombesin, cholecystokinin/gastrin, GLP-1/exendin and RGD.

Microfluidics for synthesis of peptide-based PET tracers.

Recent Advances in Microfluidic Devices for the Radiosynthesis of PET‐imaging Probes

Automated Microfluidic Chip System for Radiosynthesis of PET Imaging Probes

Micro-reactors for PET tracer labeling

Microfluidic Chip for the Synthesis of PET Radioactive Drugs

Development of a Radiotracer for PET Imaging of the SNAP Tag.

Research Progress on the Radio-Synthesis of PET Probes in Microfluidic Chips

Recent advances in photochemistry for positron emission tomography imaging

Click Labeled Peptides with Fluorine-18 for PET Imaging

Design and Application of a Batch-Reactor Microfluidic Device for Synthesis of 18F PET Tracers

[18F]fluoride Activation and 18F-Labelling in Hydrous Conditions-Towards a Microfluidic Synthesis of PET Radiopharmaceuticals

Computer-Assisted Design of Peptide-Based Radiotracers

One-step Radiosynthesis of 18F-Alf-nota-rgd2 for Tumor Angiogenesis PET Imaging

Methodological Progress of 18 F-labeled Aromatic PET Radiotracers

Dual Mode Fluorescent Pet Tracers: Efficient Modular Synthesis, Facile F-18-Radiolabelling, in Vivo Pet Imaging and Ex Vivo Fluorescence

Multistep Synthesis of A Radiolabeled Imaging Probe Using Integrated Microfluidics

Advancements in Microfluidic Cassette-Based iMiDEVTM Technology for Production of L-[11C]Methionine and [11C]Choline

Radiopharmaceutical development of radiolabelled peptides

Advances in [18F]Trifluoromethylation Chemistry for PET Imaging

Ultra-compact, automated microdroplet radiosynthesizer

Synthesis of 18F‐labeled Aryl Trifluoromethyl Sulfones, ‐Sulfoxides, and ‐Sulfides for Positron Emission Tomography